Telix Pharmaceuticals Limited (ASX:TLX)
Telix Pharmaceuticals (ASX:TLX) was created to deliver on the promise of nuclear medicine. Nuclear medicine has historically suffered from a lack of commercial critical mass and commitment to late-stage product development. Molecularly-targeted radiation (MTR) potentially offers better-informed treatment decisions and truly personalised therapy. The company's product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer.
The Telix team are experienced drug developers, clinicians and executives, with a passion for radiation biology and oncology. Telix’s pipeline currently focuses on unmet needs in cancer care, specifically in prostate, renal (kidney) and glioblastoma (brain) cancer. The company is also keenly interested in partnership and in-licensing opportunities to further expand its portfolio.
In December 2018, Telix acquired ANMI SA, a leader in the field of radiopharmaceutical development. The ANMI team brings a wealth of innovation and experience in the streamlined development and production of novel radiopharmaceuticals. For more information about ANMI, visit anmi.be.